Drug Approval | July 01, 2022
Lupin receives approval from USFDA for Paliperidone extended-release tablets
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Bringing next-gen cannabinoid therapeutics to cancer patients
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Glenmark is the first company in India to market the innovative FDC of Indacaterol
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Amarex Clinical Research guides its client to phase II of FDA trials
Subscribe To Our Newsletter & Stay Updated
